NASDAQ:GRFS Grifols (GRFS) Stock Price, News & Analysis $7.41 +0.06 (+0.82%) Closing price 04:00 PM EasternExtended Trading$7.41 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Grifols Stock (NASDAQ:GRFS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Grifols alerts:Sign Up Key Stats Today's Range$7.35▼$7.4750-Day Range$7.20▼$8.2552-Week Range$6.96▼$10.23Volume597,122 shsAverage Volume584,674 shsMarket Capitalization$5.04 billionP/E Ratio39.00Dividend Yield1.21%Price Target$10.00Consensus RatingReduce Company Overview Grifols S.A. is a global healthcare company headquartered in Barcelona, Spain, and listed on Nasdaq under the symbol GRFS. Founded in 1909, the company specializes in plasma-derived medicines and other products used to treat chronic and rare diseases. Its biopharma business develops and manufactures therapies derived from human plasma, including immunoglobulins, albumin, coagulation factors and alpha-1 antitrypsin. These products support patients with immune deficiencies, bleeding disorders, liver conditions and certain respiratory diseases. Grifols collects plasma through a network of donation centers and operates manufacturing and research facilities in multiple countries. Grifols also provides diagnostic solutions for transfusion medicine, including blood-typing, screening and laboratory systems, instruments and reagents. Its products and services are supplied to hospitals, clinical laboratories, blood banks and healthcare providers across North America, Europe and other international markets.AI Generated. May Contain Errors. Read More Grifols Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreGRFS MarketRank™: Grifols scored higher than 97% of companies evaluated by MarketBeat, and ranked 10th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingReduce Consensus RatingGrifols has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialGrifols has a consensus price target of $10.00, representing about 35.0% upside from its current price of $7.41.Amount of Analyst CoverageGrifols has only been the subject of 2 research reports in the past 90 days.Read more about Grifols' stock forecast and price target. Earnings and Valuation5.0 / 5Proj. Earnings Growth24.07% Earnings GrowthEarnings for Grifols are expected to grow by 24.07% in the coming year, from $1.08 to $1.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Grifols is 39.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 42.18.Price to Earnings Ratio vs. SectorThe P/E ratio of Grifols is 39.00, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 214.73.Price to Earnings Growth RatioGrifols has a PEG Ratio of 0.27. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioGrifols has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Grifols' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.50% of the float of Grifols has been sold short.Short Interest Ratio / Days to CoverGrifols has a short interest ratio ("days to cover") of 8.83.Change versus previous monthShort interest in Grifols has recently decreased by 0.08%, indicating that investor sentiment is improving. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldGrifols pays a meaningful dividend of 1.17%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthGrifols does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Grifols is 47.37%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Grifols will have a dividend payout ratio of 6.72% next year. This indicates that Grifols will be able to sustain or increase its dividend.Read more about Grifols' dividend. News and Social Media3.1 / 5News Sentiment0.93 News SentimentGrifols has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Grifols this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Grifols insiders have not sold or bought any company stock.Percentage Held by Insiders0.19% of the stock of Grifols is held by insiders.Percentage Held by InstitutionsGrifols has minimal institutional ownership at this time.Read more about Grifols' insider trading history. Receive GRFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GRFS Stock News HeadlinesGrifols says Canada plasma license suspension has no impactSeptember 24, 2026 | reuters.comGrifols (NASDAQ:GRFS) Upgraded by Wall Street Zen to "Buy" RatingSeptember 19, 2026 | americanbankingnews.comManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.September 28 at 1:00 AM | Monument Traders Alliance (Ad)GRFS - Grifols, S.A.September 17, 2026 | seekingalpha.comGrifols: Better Plasma Economics Can Unlock A Discounted EquitySeptember 16, 2026 | seekingalpha.comGrifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin DeficiencyAugust 10, 2026 | markets.businessinsider.comGrifols Announces Completion of SPARTA Phase 3 Trial Follow-Up for Prolastin-C in Alpha-1 EmphysemaAugust 10, 2026 | quiverquant.comQGrifols Reshapes Board and Committee Leadership After Director ResignationJuly 30, 2026 | tipranks.comSee More Headlines GRFS Stock Analysis - Frequently Asked Questions How have GRFS shares performed this year? Grifols' stock was trading at $9.35 at the start of the year. Since then, GRFS shares have decreased by 20.7% and is now trading at $7.41. How were Grifols' earnings last quarter? Grifols, S.A. (NASDAQ:GRFS) issued its earnings results on Tuesday, May, 4th. The biotechnology company reported $0.21 EPS for the quarter, missing analysts' consensus estimates of $0.22 by $0.01. The biotechnology company earned $1.43 billion during the quarter. Grifols had a trailing twelve-month return on equity of 6.21% and a net margin of 5.54%. When did Grifols' stock split? Grifols shares split on the morning of Monday, January 4th 2016.The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were distributed to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Grifols have any subsidiaries? The following companies are subsidiaries of Grifols: Biotest US Corporation, Haema AG, Goetech LLC (D/B/A Medkeeper), Kiro Robotics, Progenika Biopharma, Araclon Biotech, Talecris Biotherapeutics, and more. Who are Grifols' major shareholders? Grifols' top institutional investors include Tidal Investments LLC (0.18%), Hennion & Walsh Asset Management Inc. (0.09%), Corient Private Wealth LP (0.01%) and Engineers Gate Manager LP (0.01%). How do I buy shares of Grifols? Shares of GRFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Grifols own? Based on aggregate information from My MarketBeat watchlists, some other companies that Grifols investors own include Johnson & Johnson (JNJ), Alibaba Group (BABA), Taiwan Semiconductor Manufacturing (TSM), JPMorgan Chase & Co. (JPM), Deckers Outdoor (DECK), Vale (VALE) and Meta Platforms (META). Company Calendar Last Earnings5/04/2021Record date for 7/9 Dividend7/02/2026Ex-Dividend for 7/9 Dividend7/02/2026Dividend Payable7/09/2026Today9/28/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 GRFS's financial health is in the Yellow zone, according to TradeSmith. GRFS has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GRFS CIK1438569 Webwww.grifols.com Phone(493) 571-0221Fax34-93-571-0267Employees25,247Year Founded1909Price Target and Rating Average Price Target for Grifols$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+35.0%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$0.19 Trailing P/E Ratio39.00 Forward P/E Ratio6.86 P/E Growth0.27Net Income$454.82 million Net Margins5.54% Pretax Margin8.18% Return on Equity6.21% Return on Assets2.39% Debt Debt-to-Equity Ratio1.10 Current Ratio2.37 Quick Ratio0.81 Sales & Book Value Annual Sales$8.51 billion Price / Sales0.59 Cash Flow$1.43 per share Price / Cash Flow5.19 Book Value$12.64 per share Price / Book0.59Miscellaneous Outstanding Shares680,580,000Free Float679,282,000Market Cap$5.04 billion OptionableOptionable Beta0.67 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:GRFS) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
